國立虎尾科技大學 |

Resistance to targeted therapies in breast cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Resistance to targeted therapies in breast cancer/ edited by Jenifer R. Prosperi.
other author:	Prosperi, Jenifer R.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xv, 184 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Breast - Cancer -
Online resource:	http://dx.doi.org/10.1007/978-3-319-70142-4
ISBN:	9783319701424

Resistance to targeted therapies in breast cancer
Resistance to targeted therapies in breast cancer[electronic resource] /edited by Jenifer R. Prosperi. - Cham :Springer International Publishing :2017. - xv, 184 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.162196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.

ISBN: 9783319701424

Standard No.: 10.1007/978-3-319-70142-4doiSubjects--Topical Terms:

679326
Breast
--Cancer

LC Class. No.: RC280.B8

Dewey Class. No.: 616.99449061

Resistance to targeted therapies in breast cancer
LDR:02091nam a2200325 a 4500 001 922331
003 DE-He213
005 20171204113727.0
006 m d
007 cr nn 008maaau
008 190624s2017 gw s 0 eng d
020 $a 9783319701424 $q (electronic bk.)
020 $a 9783319701417 $q (paper)
024 7 $a 10.1007/978-3-319-70142-4 $2 doi
035 $a 978-3-319-70142-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99449061 $2 23
090 $a RC280.B8 $b R433 2017
245 0 0 $a Resistance to targeted therapies in breast cancer $h [electronic resource] / $c edited by Jenifer R. Prosperi.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a xv, 184 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.16
505 0 $a Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
520 $a We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
650 0 $a Breast $x Cancer $x Chemotherapy. $3 679326
650 0 $a Drug resistance in cancer cells. $3 681914
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
700 1 $a Prosperi, Jenifer R. $3 1197852
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 1063064
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-70142-4
950 $a Biomedical and Life Sciences (Springer-11642)